Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altus Pharmaceuticals Inc.

Division of Ajinomoto Co. Inc.

Latest From Altus Pharmaceuticals Inc.

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

Stockwatch: 2017, Year Of The Dog

News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.

Commercial Clinical Trials

Allena Pharma gains hyperoxaluria portfolio from Althea

Allena Pharmaceuticals, a US biotech set up last November to develop nonsystemic oral protein therapeutics for metabolic and orphan diseases, has obtained the exclusive worldwide rights to Althea Technologies' broad hyperoxaluria portfolio to assist in the development of its own therapy for hyperoxaluria – a condition for which there are currently no effective pharmacological treatments.

Gynecology & Urology

Georges Gemayel joins NPS Pharmaceuticals board

NPS Pharmaceuticals, a biopharmaceutical company developing orphan products for rare disorders, has appointed Dr Georges Gemayel to its board of directors. Dr Gemayel previously served as chair of FoldRx Pharmaceuticals, as well as president and CEO of Altus Pharmaceuticals from 2008-09. Prior to Altus, he was an executive vice-president of Genzyme.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Altus Biologics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ajinomoto Co. Inc.
  • Senior Management
  • Georges Gemayel, PhD, CEO
    Robert Gallotto, VP, Strategic Planning & Alliance Mgt.
    Alexey L Margolin, PhD, CSO
  • Contact Info
  • Altus Pharmaceuticals Inc.
    Phone: (617) 299-2900
    125 Sydney St.
    Cambridge, MA 02139-4807